BeiGene Reports Phase 3 Trial Meeting Primary Endpoint
BeiGene Ltd. (BGNE) reported that its Phase 3 trial assessing tislelizumab in combination with pemetrexed and platinum chemotherapy demonstrated a statistically significant improvement in progression-free survival ((PFS)) compared to pemetrexed and platinum chemotherapy alone. The findings formed a part of the planned interim analysis, as assessed by an independent review committee. The analysis did not identify any new safety signals, and the safety profile of the drug candidate used in conjunction with pemetrexed and platinum chemotherapy was in line with the already known risks associated with each